Literature DB >> 25881899

The potential role of IL-33/ST2 signaling in fibrotic diseases.

Qiaoyan Gao1, Yan Li2, Mingcai Li2.   

Abstract

IL-33, a new member of the IL-1F, is widely expressed throughout the body and can be up-regulated by stimulation with proinflammatory factors. It has been identified as a functional ligand for the plasma membrane receptor complex that is a heterodimer consisting of membrane-bound ST2L, which is a member of the IL-1R family, and IL-1RAcP. IL-33 is crucial for the induction of Th2 immune responses. Additionally, under other circumstances, it can also act as an endogenous danger signal. Recently, many studies have demonstrated that IL-33 may be related to the development and progression of fibrotic diseases. It has proinflammatory effects in some fibrotic diseases but has anti-inflammatory effects in others. In this review, the biologic characteristics of IL-33 and the role of the IL-33/ST2 signaling pathway in various fibrotic diseases will be discussed. We hope this overview will provide new insights for the treatment of these diseases. © Society for Leukocyte Biology.

Entities:  

Keywords:  cardiac fibrosis; hepatic fibrosis; pulmonary fibrosis; skin fibrosis

Mesh:

Substances:

Year:  2015        PMID: 25881899     DOI: 10.1189/jlb.3RU0115-012R

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  22 in total

1.  Uropathogenic Escherichia coli-induced fibrosis, leading to lower urinary tract symptoms, is associated with type 2 cytokine signaling.

Authors:  Ashlee Bell-Cohn; Daniel J Mazur; Christel Hall; Anthony J Schaeffer; Praveen Thumbikat
Journal:  Am J Physiol Renal Physiol       Date:  2019-01-09

Review 2.  IL-33/ST2 Axis in Organ Fibrosis.

Authors:  Ourania S Kotsiou; Konstantinos I Gourgoulianis; Sotirios G Zarogiannis
Journal:  Front Immunol       Date:  2018-10-24       Impact factor: 7.561

3.  Deficiency of GATA3-Positive Macrophages Improves Cardiac Function Following Myocardial Infarction or Pressure Overload Hypertrophy.

Authors:  Mingjie Yang; Lei Song; Lai Wang; Ada Yukht; Haley Ruther; Fuqiang Li; Minghui Qin; Homayon Ghiasi; Behrooz G Sharifi; Prediman K Shah
Journal:  J Am Coll Cardiol       Date:  2018-08-21       Impact factor: 24.094

Review 4.  Inflammatory Profiles of the Interleukin Family and Network in Cerebral Hemorrhage.

Authors:  Lei Ye; Lu Gao; Hongwei Cheng
Journal:  Cell Mol Neurobiol       Date:  2018-07-19       Impact factor: 5.046

5.  Intrarenal modulation of NF-κB activity attenuates cardiac injury in a swine model of CKD: a renal-cardio axis.

Authors:  Alejandro R Chade; Jason E Engel; Michael E Hall; Alfonso Eirin; Gene L Bidwell
Journal:  Am J Physiol Renal Physiol       Date:  2021-08-16

6.  Expression and potential roles of IL-33/ST2 in the immune regulation during Clonorchis sinensis infection.

Authors:  Qian Yu; Xiang-Yang Li; Xiao-Dan Cheng; Li-Ping Shen; Fan Fang; Bo Zhang; Hui Hua; Chao Yan; Ren-Xian Tang; Kui-Yang Zheng
Journal:  Parasitol Res       Date:  2016-03-05       Impact factor: 2.289

7.  NKp46(+) natural killer cells attenuate metabolism-induced hepatic fibrosis by regulating macrophage activation in mice.

Authors:  Annie-Carole Tosello-Trampont; Peter Krueger; Sowmya Narayanan; Susan G Landes; Norbert Leitinger; Young S Hahn
Journal:  Hepatology       Date:  2016-01-21       Impact factor: 17.425

Review 8.  The IL-1 cytokine family and its role in inflammation and fibrosis in the lung.

Authors:  L A Borthwick
Journal:  Semin Immunopathol       Date:  2016-03-21       Impact factor: 9.623

9.  Interplay between hypoxia and inflammation contributes to the progression and severity of respiratory viral diseases.

Authors:  Sulagna Bhattacharya; Sakshi Agarwal; Nishith M Shrimali; Prasenjit Guchhait
Journal:  Mol Aspects Med       Date:  2021-07-19

Review 10.  Innate Immunity and Biomaterials at the Nexus: Friends or Foes.

Authors:  Susan N Christo; Kerrilyn R Diener; Akash Bachhuka; Krasimir Vasilev; John D Hayball
Journal:  Biomed Res Int       Date:  2015-07-12       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.